HRP20191872T1 - Sirp-alfa imunoglobulin fuzijski proteini - Google Patents

Sirp-alfa imunoglobulin fuzijski proteini Download PDF

Info

Publication number
HRP20191872T1
HRP20191872T1 HRP20191872TT HRP20191872T HRP20191872T1 HR P20191872 T1 HRP20191872 T1 HR P20191872T1 HR P20191872T T HRP20191872T T HR P20191872TT HR P20191872 T HRP20191872 T HR P20191872T HR P20191872 T1 HRP20191872 T1 HR P20191872T1
Authority
HR
Croatia
Prior art keywords
seq
residues
fusion protein
sirpα
antibody
Prior art date
Application number
HRP20191872TT
Other languages
English (en)
Croatian (hr)
Inventor
Kin-Ming Lo
Nora ZIZLSPERGER
Aroop SIRCAR
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53872055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191872(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20191872T1 publication Critical patent/HRP20191872T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HRP20191872TT 2014-08-15 2015-08-14 Sirp-alfa imunoglobulin fuzijski proteini HRP20191872T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038196P 2014-08-15 2014-08-15
PCT/EP2015/068798 WO2016024021A1 (en) 2014-08-15 2015-08-14 Sirp-alpha immunoglobulin fusion proteins
EP15750744.3A EP3180363B2 (en) 2014-08-15 2015-08-14 Sirp-alpha immunoglobulin fusion proteins

Publications (1)

Publication Number Publication Date
HRP20191872T1 true HRP20191872T1 (hr) 2020-02-07

Family

ID=53872055

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191872TT HRP20191872T1 (hr) 2014-08-15 2015-08-14 Sirp-alfa imunoglobulin fuzijski proteini

Country Status (22)

Country Link
US (1) US11021694B2 (enExample)
EP (2) EP3180363B2 (enExample)
JP (1) JP6764858B2 (enExample)
KR (1) KR20170036796A (enExample)
CN (1) CN107108748A (enExample)
AU (1) AU2015303135B2 (enExample)
BR (1) BR112017002646A2 (enExample)
CA (1) CA2956126A1 (enExample)
DK (1) DK3180363T3 (enExample)
ES (1) ES2751915T5 (enExample)
HR (1) HRP20191872T1 (enExample)
HU (1) HUE046661T2 (enExample)
IL (1) IL250622B2 (enExample)
LT (1) LT3180363T (enExample)
MX (1) MX377196B (enExample)
PL (1) PL3180363T3 (enExample)
PT (1) PT3180363T (enExample)
RU (1) RU2017108203A (enExample)
SG (1) SG11201701189TA (enExample)
SI (1) SI3180363T1 (enExample)
WO (1) WO2016024021A1 (enExample)
ZA (1) ZA201701810B (enExample)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
ES2751915T5 (es) 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
SG11201707182WA (en) * 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CN107149682B (zh) * 2016-03-04 2022-01-04 复旦大学 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法
WO2017184553A1 (en) * 2016-04-18 2017-10-26 Baylor College Of Medicine Cancer gene therapy targeting cd47
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
WO2018008470A1 (ja) * 2016-07-05 2018-01-11 国立大学法人神戸大学 抗腫瘍剤
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
SG10201913263SA (en) 2016-09-29 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用
WO2018090950A1 (zh) 2016-11-18 2018-05-24 北京韩美药品有限公司 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN108220228A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11267856B2 (en) 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
JP7244428B2 (ja) 2017-02-27 2023-03-22 シャタック ラボ，インコーポレイテッド Ｖｓｉｇ８ベースのキメラタンパク質
IL268198B2 (en) 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN108623689B (zh) * 2017-03-15 2020-10-16 宜明昂科生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制备方法和用途
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CN108864290B (zh) * 2017-05-08 2021-12-07 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
CN111448323B (zh) * 2017-06-07 2023-12-01 长源赋能(上海)生命科技有限公司 精确制导的多功能治疗抗体
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
WO2019043059A1 (en) * 2017-08-30 2019-03-07 Symphogen A/S COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY ANTI-EGFR ANTIBODIES
WO2019047885A1 (en) * 2017-09-07 2019-03-14 Dingfu Biotarget Co., Ltd. IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
WO2019066536A1 (ko) * 2017-09-28 2019-04-04 한국과학기술연구원 신규 암 치료용 조성물
CN119264274A (zh) * 2017-10-12 2025-01-07 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
CN111278865B (zh) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
KR102366853B1 (ko) * 2017-11-10 2022-02-23 아이-맵 바이오파마 유에스 리미티드 Cd47 항체 및 사이토카인을 포함하는 융합 단백질
US12110332B2 (en) 2017-11-20 2024-10-08 Taizhou Mabtech Pharmaceutical Co., Ltd. Bifunctional fusion protein targeting CD47 and PD-L1
CA3084626A1 (en) 2017-12-04 2019-06-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
WO2019109357A1 (zh) * 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 抗pd-1/cd47的双特异性抗体及其应用
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3765080A4 (en) * 2018-03-13 2022-03-16 Trillium Therapeutics Inc. IMPROVEMENTS IN THERAPY FOR CD47 BLOCKADE BY EGFR ANTIBODIES
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CN110386984B (zh) * 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
CN108794641A (zh) * 2018-07-04 2018-11-13 上海科医联创生物科技有限公司 一种针对EGFRvIII的多功能融合蛋白及其应用
CA3104780A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
JP7193058B2 (ja) * 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質
JP2022512540A (ja) 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Ｆｌｔ３ｌ系キメラタンパク質
EP3846855B1 (en) 2018-09-04 2024-12-04 Pfizer Inc. Cd47 blockade with parp inhibition for disease treatment
CN109535258A (zh) * 2018-10-26 2019-03-29 上海科弈药业科技有限公司 一种针对Her2+肿瘤的多功能融合蛋白及其应用
GB2596411B (en) * 2018-10-29 2023-09-20 Tigatx Inc Compositions and methods comprising IgA antibody constructs
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
EP3880248A4 (en) * 2018-11-14 2022-08-10 JN Biosciences, LLC MULTIMERIC HYBRID FC PROTEINS FOR IV IG REPLACEMENT
CN113412279B (zh) * 2018-11-15 2024-09-24 拜奥迪斯私人有限公司 人源化抗SIRPα抗体
CN109517054B (zh) * 2018-12-04 2022-04-08 江苏东抗生物医药科技有限公司 SIRPα变体或其融合蛋白及其应用
CN109535263B (zh) * 2018-12-04 2022-06-17 江苏东抗生物医药科技有限公司 SIRPα突变体及其融合蛋白
US20220056135A1 (en) * 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
EP3936526A4 (en) * 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
TW202104260A (zh) * 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
CN114222586A (zh) * 2019-06-14 2022-03-22 斯克里普斯研究学院 免疫检查点阻断性双特异性分子
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4039711A4 (en) * 2019-07-23 2023-11-15 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof
JP7723420B2 (ja) * 2019-08-28 2025-08-14 キングス・カレッジ・ロンドン Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CN115038718B (zh) * 2019-11-08 2024-07-02 山东先声生物制药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
CA3193073A1 (en) * 2020-09-17 2022-03-24 Liping SONG Bispecific recombinant protein and use thereof
JP2023545983A (ja) * 2020-10-07 2023-11-01 セルジーン コーポレイション リンパ系悪性腫瘍状態の二重特異性抗体治療
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN112656941A (zh) * 2021-01-20 2021-04-16 福建医科大学附属协和医院 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
EP4320156A1 (en) * 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
WO2023003331A1 (en) * 2021-07-19 2023-01-26 Yuhan Corporation Sirp-alpha variants and use thereof
CN120329453A (zh) * 2021-07-19 2025-07-18 百奥泰生物制药股份有限公司 基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023072217A1 (en) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Fusion proteins targeting cd3 and cd47
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
EP4319796A4 (en) * 2021-12-21 2025-07-23 Fbd Biologics Ltd MODIFIED SIRPalpha VARIANTS AND METHODS OF USE THEREOF
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022435471A1 (en) * 2022-01-18 2024-05-30 Fbd Biologics Limited Cd47/pd-l1-targeting protein complex and methods of use thereof
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023183890A1 (en) * 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Multivalent sirp-alpha fusion polypeptides
JP2025510774A (ja) 2022-03-24 2025-04-15 ビタールート・バイオ・インコーポレイテッド 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド
KR20240162568A (ko) * 2022-03-25 2024-11-15 우시 바이올로직스 아일랜드 리미티드 항-her2/항-cd47 분자 및 이의 용도
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN120923632A (zh) * 2022-05-06 2025-11-11 正大天晴药业集团股份有限公司 靶向cd40和cd47的重组融合蛋白
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
AU2023285109A1 (en) * 2022-06-10 2024-12-12 Incyte Corporation Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
CN116041470B (zh) * 2022-08-04 2024-10-22 四川大学华西医院 具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4592316A1 (en) * 2022-09-23 2025-07-30 Lindis Biotech GmbH Isolated antigen-binding protein and use thereof
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118546255A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
EP4683654A1 (en) * 2023-03-22 2026-01-28 Li, Wangzhi Sirp variants and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2024245380A1 (en) 2023-05-31 2024-12-05 Fbd Biologics Limited Cd47/pd-l1-targeting protein complex and methods of use thereof
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025247303A1 (zh) * 2024-05-30 2025-12-04 上海艾乐晞生物科技有限公司 具有pH依赖结合活性的人信号调节蛋白α突变体及其应用
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors
CN121824730A (zh) * 2026-03-09 2026-04-10 上海荣昌生物科技有限公司 一种多肽、融合蛋白、双特异性抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JP2011500005A (ja) 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
BRPI0923442A2 (pt) 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
DK2429574T3 (da) * 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP2970485A1 (en) 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
JP6355032B2 (ja) 2014-03-24 2018-07-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換え二機能性融合タンパク質、それらの調製および使用
EP3188758B1 (en) 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
ES2751915T5 (es) 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa

Also Published As

Publication number Publication date
SI3180363T1 (sl) 2020-05-29
DK3180363T3 (da) 2019-11-04
IL250622B (en) 2022-12-01
RU2017108203A (ru) 2018-09-17
PL3180363T3 (pl) 2020-02-28
US11021694B2 (en) 2021-06-01
BR112017002646A2 (pt) 2018-02-27
AU2015303135A1 (en) 2017-02-23
EP3643727A1 (en) 2020-04-29
SG11201701189TA (en) 2017-03-30
KR20170036796A (ko) 2017-04-03
ES2751915T3 (es) 2020-04-02
JP2017525698A (ja) 2017-09-07
ZA201701810B (en) 2020-10-28
US20160177276A1 (en) 2016-06-23
LT3180363T (lt) 2019-11-25
EP3180363B1 (en) 2019-09-25
JP6764858B2 (ja) 2020-10-07
MX2017001712A (es) 2017-04-27
EP3180363B2 (en) 2022-09-14
EP3180363A1 (en) 2017-06-21
IL250622A0 (en) 2017-04-30
ES2751915T5 (es) 2022-12-23
MX377196B (es) 2025-03-07
HUE046661T2 (hu) 2020-03-30
CA2956126A1 (en) 2016-02-18
AU2015303135B2 (en) 2021-05-20
RU2017108203A3 (enExample) 2019-03-13
IL250622B2 (en) 2023-04-01
WO2016024021A1 (en) 2016-02-18
CN107108748A (zh) 2017-08-29
PT3180363T (pt) 2019-11-05

Similar Documents

Publication Publication Date Title
RU2017108203A (ru) Слитые белки sirp-альфа с иммуноглобулином
JP2017525698A5 (enExample)
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20210977T1 (hr) Ciljano inhibiranje tgf beta
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2020063262A5 (enExample)
HRP20200679T1 (hr) Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
JP2019532619A5 (enExample)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
FI3227342T4 (fi) Proteiininen heterodimeeri ja sen käyttö
WO2016191246A3 (en) T cell receptor-like antibodies specific for a prame peptide
FI3240805T3 (fi) Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
AR077088A1 (es) Proteinas biespecificas de union a antigeno
IL295295A (en) Antibodies targeting fc receptor-like 5 and methods of use
FI3348571T3 (fi) Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini
JP2018517431A5 (enExample)
PE20241587A1 (es) Receptores de antigenos quimericos que se dirigen a flt3
HRP20192347T1 (hr) Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
RU2015144098A (ru) Четырехвалентные биспецифические антитела
HRP20170462T1 (hr) Protutijela za epidermalni receptor 3 faktora rasta (her3)
WO2017060322A3 (en) Ptefb-inhibitor-adc